<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02596984</url>
  </required_header>
  <id_info>
    <org_study_id>1308173</org_study_id>
    <secondary_id>140413A-41</secondary_id>
    <secondary_id>2014-000789-22</secondary_id>
    <nct_id>NCT02596984</nct_id>
  </id_info>
  <brief_title>Evaluation of the Pharmacokinetics of Caspofungin in ICU Patients</brief_title>
  <acronym>CaspoKin</acronym>
  <official_title>Evaluation of the Pharmacokinetics of Caspofungin in ICU Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Although the pharmacokinetics of Caspofungin has been studied in healthy subjects and
      patients, only a few studies have been performed in critically-ill patients. In these
      patients several factors, including sepsis, shock, increased distribution volume, hepatic
      dysfunction and hypoalbuminemia may result in dramatic changes in antibiotic concentrations
      and pharmacokinetics. Caspofungin pharmacokinetic data is scarce and are results mainly from
      case series or animal studies. Thus, studies performed so far show Caspofungin trough
      concentrations either decreased, similar to usual value in non-critically ill patients or
      increased. One of these studies suggested that body weight and hypoalbuminemia may be the
      main factors associated with Caspofungin pharmacokinetic variability. Pharmacokinetic
      parameters of caspofungin in pigs with hypovolemic shock suggested the peripheral volume of
      distribution of caspofungin and intercompartmental clearance to be higher than in healthy
      animals. These results are however preliminary and cannot be extrapolated suggesting further
      clinical studies in human to be needed.

      The primary objective of this study is to assess Caspofungin trough concentrations and
      pharmacokinetics in critically-ill patients requiring vasopressors.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 16, 2015</start_date>
  <completion_date type="Anticipated">February 2018</completion_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Caspofungin pharmacokinetic : clearance (ml.min-1)</measure>
    <time_frame>day 2 - day 3 - day 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Caspofungin pharmacokinetic : volume of distribution (mL)</measure>
    <time_frame>day 2 - day 3 - day 4</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Caspofungin trough concentration</measure>
    <time_frame>day 2 - day 3 - day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of patients for whom the trough concentrations are lower than the MIC (Minimum Inhibitory Concentration) 90 of Candida ( 1mg / L)</measure>
    <time_frame>day 2 - day 3 - day 4</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Shock</condition>
  <arm_group>
    <arm_group_label>caspofungin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Caspofungin will be administered according to the international recommendation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Caspofungin</intervention_name>
    <description>Either preemptive, empirical or curative prescription of Caspofungin by one of the ICUs' attending physician. Caspofungin will be administered according to the international recommendation</description>
    <arm_group_label>caspofungin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients (age &gt; 18 y.o)

          -  Either preemptive, empirical or curative prescription of Caspofungin by one of the
             ICUs' attending physician

          -  Requiring vasopressors

          -  Admission in one of the participating ICUs.

        Exclusion Criteria:

          -  Pregnancy

          -  Lack of affiliation to the National Medical Insurance

          -  Previous inclusion in the study

          -  Inclusion in a concomitant study that may interact with the current study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael DARMON, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de SAINT-ETIENNE</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael DARMON, MD PhD</last_name>
    <phone>(0)477127853</phone>
    <phone_ext>+33</phone_ext>
    <email>michael.darmon@chu-st-etienne.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de CLERMONT-FERRAND</name>
      <address>
        <city>Clermont-ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bertrand SOUWEINE, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>Bertrand SOUWEINE, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HÃ´pital Saint-Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elie AZOULAY, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>Matthieu LEGRAND, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elie AZOULAY, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de SAINT-ETIENNE</name>
      <address>
        <city>Saint-etienne</city>
        <zip>42000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mickael DARMON, MD PhD</last_name>
      <phone>(0)477127853</phone>
      <phone_ext>+33</phone_ext>
      <email>michael.darmon@chu-st-etienne.fr</email>
    </contact>
    <investigator>
      <last_name>Christophe MARIAT, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bernard TARDY, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael DARMON, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 2015</study_first_submitted>
  <study_first_submitted_qc>November 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2015</study_first_posted>
  <last_update_submitted>January 26, 2018</last_update_submitted>
  <last_update_submitted_qc>January 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Intensive Care Unit</keyword>
  <keyword>Shock</keyword>
  <keyword>Antifungal agent</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Sepsis</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Caspofungin</mesh_term>
    <mesh_term>Echinocandins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

